Title |
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
|
---|---|
Published in |
OncoTargets and therapy, April 2017
|
DOI | 10.2147/ott.s133385 |
Pubmed ID | |
Authors |
Cristina Ilcus, Cristina Bagacean, Adrian Tempescul, Cristian Popescu, Andrada Parvu, Mihai Cenariu, Corina Bocsan, Mihnea Zdrenghea |
Abstract |
The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immune evasion mechanism. Blocking of the PD-1-PD-L signaling axis has recently been shown to be effective and was clinically approved in relapsed/refractory tumors such as malignant melanoma and lung cancer, but also classical Hodgkin's lymphoma. A plethora of trials exploring PD-1 blockade in cancer are ongoing. Here, we review the role of PD-1 signaling in lymphoid malignancies, and the latest results of trials investigating PD-1 or PD-L1 blocking agents in this group of diseases. Early phase studies proved very promising, leading to the clinical approval of a PD-1 blocking agent in Hodgkin's lymphoma, and Phase III clinical studies are either planned or ongoing in most lymphoid malignancies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 85 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 11 | 13% |
Researcher | 9 | 11% |
Student > Bachelor | 9 | 11% |
Other | 7 | 8% |
Student > Doctoral Student | 5 | 6% |
Other | 15 | 18% |
Unknown | 29 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 25% |
Biochemistry, Genetics and Molecular Biology | 11 | 13% |
Immunology and Microbiology | 7 | 8% |
Agricultural and Biological Sciences | 4 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Other | 5 | 6% |
Unknown | 33 | 39% |